
June 23 (Reuters) - Oryzon Genomics SA ORY.MC:
SUBMITS TO FDA CLINICAL TRIAL PROTOCOL FOR ITS PHASE III PORTICO-2 TRIAL OF VAFIDEMSTAT IN BORDERLINE PERSONALITY DISORDER (BPD) PATIENTS
PORTICO-2 TO EMPLOY TWO CLINICAL OUTCOME MEASURES FOR AGGRESSION AS PRIMARY ENDPOINT
TO EMPLOY OVERT AGGRESSION SCALE-MODIFIED (OAS-M) AS KEY SECONDARY ENDPOINT
ADDITIONAL SECONDARY ENDPOINTS TO EVALUATE BROADER CLINICAL IMPROVEMENTS IN BPD SYMPTOMATOLOGY AND LIFE QUALITY